Bluejay Diagnostics shares surge 10.66% premarket after announcing $4.5M private placement for FDA approval and R&D.

Bluejay Diagnostics (NASDAQ:BJDX) surged 10.66% in premarket trading following two key announcements on October 9–10, 2025. The company closed a $4.5 million private placement priced at-the-market under Nasdaq rules, providing capital for FDA approval and R&D activities. Concurrently, it expanded its strategic partnership with SanyoSeiko to advance commercialization of the Symphony platform, signaling progress in product development and market expansion. These developments were widely covered in trusted news outlets, including GlobeNewswire and QuiverQuant, and reflect strengthened financial positioning and operational momentum, likely driving the premarket rally.